United States influenza vaccines market size to surpass USD 7,000 million by 2030

The latest business intelligence report on ‘United States influenza vaccines market’ attempts to deliver credible forecasts pertaining to the growth patterns of this business sphere over the analysis period 2021-2030.


Pune, India, March 29, 2022 (GLOBE NEWSWIRE) -- According to MarketStudyReport, United States influenza vaccines market is anticipated to register a CAGR of 6.9% during the forecast period 2021-2030 and subsequently amass a valuation of USD 7,007 million by the end of the stipulated timeframe. Increasing outbreaks due to genetic variations in influenza viruses along with increasing R&D for the development of efficacious vaccines serves as a major growth propeller for the industry.


The research stresses on the major growth propellers and opportunities, as well as the challenges and their solutions. Moreover, it meticulously examines the effectiveness of the influenza vaccines in the United States, the available rapid diagnostic testing methods, and distribution channels. It also sheds light on the reimbursement and regulatory scenarios of the industry.

Under the competitive landscape section, the document houses comprehensive data of the key players and emerging contenders with respect to their current vaccines portfolios, promising vaccines in the pipeline, platform technology, and other major developments.

Request Sample copy of this Report @ https://www.marketstudyreport.com/request-a-sample/4751537/

Notably, the number of influenza cases in the U.S. reached 29 million during 2018-2019, with around 380,000 hospitalizations and 28,000 deaths. In the following season of 2019-2020, the cases reached 38 million while hospitalizations were around the same range and the death toll stood at 20,000, as per the Centers for Disease Control and Prevention.

Apart from the high prevalence of the disease, positive reimbursement scenery is enhancing the growth of influenza vaccines market in the United States. For instance, the Centers for Medicare & Medicaid Services (CMS) offers 100% reimbursement of the costs of one seasonal influenza virus vaccination per influenza season.

Increasing emphasis of U.S. government agencies towards collaborations in an effort to boost vaccine supply is further adding traction to the industry expansion. However, vaccine shortage due to genetic differentiation of viral strains and the constant burden on manufacturers to update vaccines may slowdown market progress over the analysis period.

Competitive landscape overview:

AstraZeneca plc, Seqirus, GlaxoSmithKline plc, Sanofi S.A., Versatope Therapeutics Inc., EpiVax Inc., Imutex Ltd., FluGen Inc., Daiichi Sankyo Co., Altimmune Inc., Pneumagen Ltd., Moderna Inc., Medicago Inc., BiondVax Pharmaceuticals Ltd., and Novavax Inc. are the major players influencing United States influenza vaccines market trends.

Key players are directing their efforts toward strategic mergers and acquisitions to address the surging demand for vaccines. For instance, Sanofi acquired Protein Sciences Corporation in August 2017 and added Flublok to its portfolio, the only U.S. FDA-approved recombinant protein-based influenza vaccine. This allowed Sanofi expanded to not only expand its vaccine portfolio but expand its U.S. presence by leveraging non-egg-based manufacturing technologies.

To access a sample copy or view this report in detail along with the table of contents, please click the link below:

https://www.marketstudyreport.com/reports/united-states-influenza-vaccines-market-focus-on-persons-vaccinated-pricing-production-supply-promising-influenza-vaccines-clinical-trials-regulatory-reimbursement-distribution-channel-major-deals-key-players-recent-developments-size-share-trends-analysis-demand-opportunity-and-forecast-2022-2030

United States Influenza Vaccines Market Competitive Dashboard (Value, USD Million, 2015-2030)

  • AstraZeneca plc
  • Seqirus
  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Versatope Therapeutics Inc.
  • EpiVax Inc.
  • Imutex Ltd.
  • FluGen Inc.
  • Daiichi Sankyo Co.
  • Altimmune Inc.
  • Pneumagen Ltd.
  • Moderna Inc.
  • Medicago Inc.
  • BiondVax Pharmaceuticals Ltd.
  • Novavax Inc.

Table of Content:

1. Executive Summary

2. United States Influenza Vaccines Market Size, Insights, Analysis and Forecasts (2015 - 2030)

3. United States Number of Persons Vaccinated with Influenza Vaccines (2015 - 2030)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines

4. Key Market Growth Drivers and Challenges of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Challenges

5. United States Influenza Vaccines Pricing Analysis, Trends and Insights

6. United States Influenza Vaccines Production, Supply, and Allocation (By Companies)

7. United States Influenza Vaccines Distribution and Demand Analysis (2010 - 2021)

8. Effectiveness of Influenza Vaccines in the United States (2004 - 2021)

9. Rapid Diagnostic Testing for the Management of Influenza

10. Distribution Channel and Technique Detailed Insights of Influenza Vaccination in the United States

11. Reimbursement Environment of the United States Influenza Vaccines Market

12. Regulatory Framework of the United States Influenza Vaccines Market

13. Major Deals and Agreement Activities in the Influenza Vaccines Market
13.1 Merger and Acquisitions
13.2 Collaboration Deals
13.3 Licensing Agreement
13.4 Exclusive Agreement
13.5 Distribution Agreement

14. Promising Influenza Vaccines in the Clinical Development

15. Influenza Vaccines Clinical Trial Insights by Phase, Company and Country


Related Report:

Global Covid-19 Vaccine Market - Analysis By Product Type, Patient Type, End User, By Region, By Country (2021 Edition): Market Insights, Competition and Forecast (2020-2030)

Global Covid-19 vaccine Market will be valued at approximately USD 25 billion in the year 2024. The growing government support for vaccine development and the increasing involvement of global organizations in the development of adequate vaccination facilities in endemic regions is anticipated to positively influence the sales of Coronavirus vaccine in the upcoming years. Moreover, the strong demand for coronavirus vaccine, the ongoing initiative initiatives by governments to procure the vaccine and the waves of infection is likely to drive the market growth during the forecast period. Among the regions, North America, followed by Europe and Asia Pacific, will experience remarkable growth owing to the second and third wave of spread of the virus, emergence of mutant viruses, presence of various leading global manufacturers in the region with companies ramping up their production capacity and growing number of coronavirus patients.

About US:

Market Study Report is a hub for market intelligence products and services.

We streamline the purchase of your market research reports and services through a single integrated platform by bringing all the major publishers and their services at one place.

Our customers partner with Market Study Report, to ease their search and evaluation of market intelligence products and services and in turn focus on their company's core activities.

If you are looking for research reports on global or regional markets, competitive information, emerging markets and trends or just looking to stay on top of the curve then Market Study Report, is the platform that can help you in achieving any of these objectives.

 
 

Coordonnées